Urovant Sciences, Inc

74 articles with Urovant Sciences, Inc

• Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference

  9/8/2020

  Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually. A live, audio webcast for this event will be available on the Investor Relations sectio

• Urovant Sciences Reports Fiscal First Quarter 2020 Results

  8/13/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.

• Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

  8/6/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The con

• Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

  6/18/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.

• Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals

  6/18/2020

  Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. The co-promotion agreement will enable

• Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results

  6/11/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The conf

• Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access

  6/2/2020

  Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years’ experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston spent the last 12 years with Astellas Pharma, most recently as Senior Vice President, Urology and Hospital Business Unit. Prior to Astellas Pharma, he spent 18 years with Pfizer Kenton Stewart , a 30-year industry veteran, brin

• 

  BioSpace Movers & Shakers, May 29

  5/29/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Urovant Sciences Appoints James Hindman to Board of Directors

  5/27/2020

  James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis

• Urovant Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Urovant Sciences announced that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually.

• Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting

  5/14/2020

  52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study ( NCT03583372 ) and data by age groups from the 12-week placebo-controlled EMPOWUR study ( NCT03492281 ) will be pr

• Urovant Sciences Appoints James Robinson as President and Chief Executive Officer

  3/23/2020

  Urovant Sciences (Nasdaq: UROV) today announced the appointment of accomplished industry veteran Jim Robinson to the position of President and Chief Executive Officer.

• Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder

  3/5/2020

  Urovant Sciences (Nasdaq: UROV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for once-daily 75 mg vibegron for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

• Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

  3/2/2020

  Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

• Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference

  2/25/2020

  Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company’s 40th Annual Health Care Conference in Boston.

• Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results

  2/13/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019.

• Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results

  2/6/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020.

• Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder

  2/4/2020

  Urovant Sciences announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two double-blind, placebo-controlled randomized Phase 1 trials.

• Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell

  1/17/2020

  Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin and other Urovant executives will ring the opening bell of the Nasdaq Stock Market on Tuesday, January 21, 2020, at 9:30 a.m. Eastern.

• 

  M&A for 2019 was Big; Will 2020 Be Even Bigger?

  1/13/2020

  Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.